Emulsomes are premier vehicles for APIs with low aqueous solubility (Class II and IV drugs under the Biopharmaceutics Classification System). By dissolving the hydrophobic drug within the solid lipid core, Emulsomes circumvent solubility limitations, drastically enhancing the effective concentration available for absorption. This capability is critical for optimizing oral and intravenous formulations where poor solubility often necessitates toxic excipients.
Emulsome based Targeted Drug Delivery Solution
In the pursuit of groundbreaking therapies, the journey from a promising molecule to a viable treatment often stalls at a single, formidable obstacle: delivery. Protecting fragile payloads and guiding therapeutics to their precise site of action are challenges that can make or break a project, particularly for poorly soluble compounds. Our Creative Biolabs Emulsomes -based Delivery Systems Solution helps you enhance drug solubility, stability, and therapeutic bioavailability through innovative hybrid nanocarrier engineering and precise formulation optimization.
Click Here to View more about our Services
Introduction to Emulsome Delivery Systems
Emulsomes are a cutting-edge class of lipid-based nanocarriers that strategically merge the structural benefits of both liposomes and solid lipid nanoparticles. This hybrid design features a solid lipid core (typically composed of solid triglycerides or waxes) that is fully encapsulated by one or more phospholipid bilayers.
Fig.1 Structure of Emulsome.1,4
This architecture is fundamental to their utility: the solid core offers superior physical stability and high loading capacity for highly lipophilic drugs, while the phospholipid shell mimics biological membranes, enhancing biocompatibility and facilitating surface modification. This dual compartment structure—the solid core for hydrophobic molecules and the aqueous space between lipid layers for hydrophilic or amphiphilic compounds—allows Emulsomes to significantly boost the solubility and bioavailability of APIs that struggle with conventional delivery methods.
Scientific literature consistently highlights the stability advantage of Emulsomes. Unlike traditional oil-in-water emulsions, the solid core prevents the coalescence and physical degradation that limit the shelf life of liquid systems. Furthermore, compared to classic liposomes, the solid nature of the core reduces drug leakage, providing a genuinely sustained and controlled release profile, often prolonging drug effectiveness up to 24 hours or more, compared to the typically shorter half-life of conventional liposomal preparations.
Versatile Therapeutic Applications of Emulsomes
The robust design and tunable surface chemistry of Emulsome delivery systems enable a broad spectrum of pharmaceutical applications, transforming the therapeutic potential of challenging compounds across multiple disease areas.
Enhancement of Poorly Water-Soluble Drugs
Targeting Cancer and Autoimmune Conditions
The small, controlled size of Emulsomes (often in the range of 100–300 nm) allows them to exploit the Enhanced Permeability and Retention (EPR) effect in tumor tissues, facilitating passive accumulation at the disease site. For active targeting, the phospholipid bilayer surface is readily modified (e.g., through PEGylation or conjugation with targeting ligands like antibodies, peptides, or aptamers) to specifically bind receptors overexpressed on cancer cells or immune cells, significantly increasing local drug concentration and minimizing off-target effects. Promising results have been shown in treating breast, prostate, and colon cancers, where targeted delivery reduces systemic toxicity of potent cytotoxics.
Infectious Disease and Dermal Therapy
Emulsomes provide protection against metabolic degradation from gastric enzymes and harsh physiological environments, making them effective for delivering drugs to fight viral and fungal infections. Their superior stability and controlled release profile are especially beneficial for long-acting antimicrobial therapies. Additionally, their lipid composition makes them excellent carriers for topical and dermal applications, improving skin penetration and localized retention for sustained therapeutic action in treating conditions like microbial infections and inflammation.
Practical Research Case Studies
Brain Drug Delivery
A Tailored Thermosensitive PLGA-PEG-PLGA/Emulsomes Composite for Enhanced Oxcarbazepine Brain Delivery via the Nasal Route
Researchers developed thermosensitive PLGA-PEG-PLGA/Emulsomes composites loaded with Oxcarbazepine to bypass the Blood-Brain Barrier (BBB) for epilepsy treatment. The intranasal delivery system enhanced drug absorption and achieved significantly higher brain concentrations compared to intravenous injection. The solid core/polymeric shell hybrid structure offered superior stability and a prolonged release profile, demonstrating a viable non-invasive strategy for CNS targeting.2,4
Active Targeting
S-layer fusion protein as a tool functionalizing emulsomes and Curcu Emulsomes for antibody binding and targeting
This study focused on using S-layer fusion proteins to functionalize Curcumin-loaded Emulsomes (Curcu Emulsomes) to enable active targeting capabilities. The S-layer provided a robust, biocompatible surface for antibody conjugation. The system successfully demonstrated enhanced binding to specific target sites in vitro, offering a promising strategy to improve the bioavailability and targeted delivery of the poorly soluble natural compound Curcumin to cancer cells while maintaining controlled release characteristics.3,4
What We Can Offer: Tailored Emulsome Development Service
The challenge of formulating hydrophobic drugs, or those susceptible to rapid degradation, demands an advanced solution beyond traditional liposomes or emulsions. Emulsomes, with their unique structure, provide the superior stability and dual-loading capacity necessary to overcome these hurdles.
At Creative Biolabs, we specialize in customizing the Emulsome platform to meet the exact physicochemical demands of your active pharmaceutical ingredient (API). We move beyond generic carriers to design systems that maximize drug entrapment, control release kinetics over extended periods, and enable advanced targeting strategies. Our expertise ensures your drug candidate maintains stability through manufacturing, storage, and biological circulation, ultimately leading to improved therapeutic indices and reduced systemic toxicity.
We provide comprehensive formulation development, rigorous characterization (including particle size, zeta potential, and encapsulation efficiency), and large-scale manufacturing support, de-risking your preclinical and clinical development phases.
FAQs
How do these novel lipid carriers offer better stability for my therapeutic molecule compared to simple emulsions or standard liposomes?
These carriers utilize a core of solid or semi-solid lipid material, which is enveloped by a stabilizing phospholipid layer. This solid core acts as a rigid reservoir for the drug, preventing the rapid fusion and aggregation common in liquid-core emulsions and significantly minimizing drug leakage that often plagues conventional liposomes. The result is a formulation with a much longer shelf life and enhanced protection against degradation in biological fluids.
Can these systems successfully encapsulate both highly hydrophobic and water-soluble compounds simultaneously?
Yes, this is one of their primary strengths. Their structure is inherently dual-compartmental: highly lipid-soluble drugs are sequestered into the central solid core, while the phospholipid bilayer and the space between the multiple lipid layers can accommodate hydrophilic or amphiphilic molecules. This allows for multi-drug loading or co-delivery of an API alongside a targeting or stabilizing agent.
What are the primary formulation parameters that can be adjusted to control the drug's release rate in vivo?
The release kinetics are highly tunable. The most critical parameters involve the composition of the inner solid lipid core (specifically, the melting point and crystallinity of the core material) and the composition and fluidity of the outer phospholipid bilayer (using components like cholesterol or varying the saturation of the phospholipids). By carefully controlling these factors, we can modulate the dissolution rate and membrane permeability to achieve immediate, sustained, or pulsed release profiles.
Are these advanced delivery systems suitable for targeting specific organs, such as the brain or tumor tissue?
Absolutely. Their nanometric size is ideal for passive targeting through the EPR effect in tumors. More importantly, the robust phospholipid outer shell allows for precise chemical modification—such as coupling with specific ligands or coating with polymers—to achieve active targeting. This surface functionalization enables highly selective binding and enhanced uptake into specific cell types or allows the carrier to effectively cross physiological barriers, including the blood-brain barrier via specialized routes.
What initial information about my drug molecule is most critical for starting the formulation optimization process?
To achieve the fastest and most efficient optimization, we primarily need the following data: the molecule's octanol-water partition coefficient to determine its hydrophobicity, its aqueous solubility profile, and the drug's stability characteristics (e.g., sensitivity to pH or enzymatic degradation). This initial data guides the selection of the optimal solid lipid core and phospholipid composition.
Creative Biolabs' Emulsomes -based Delivery Systems Solution represents the next evolution in lipid-based drug delivery, offering unprecedented stability, dual-loading capability, and highly tunable release kinetics. We provide the specialized scientific platform and expert services necessary to transform your challenging API into a high-performance therapeutic product, mitigating formulation risks and accelerating your pipeline.
Reference
- Singh, Shivam, et al. "Emulsomes: new lipidic carriers for drug delivery with special mention to brain drug transport." Future journal of pharmaceutical sciences 9.1 (2023): 78. https://doi.org/10.1186/s43094-023-00530-z.
- El-Zaafarany, Ghada M et al. "A Tailored Thermosensitive PLGA-PEG-PLGA/Emulsomes Composite for Enhanced Oxcarbazepine Brain Delivery via the Nasal Route." Pharmaceutics vol. 10,4 217. 5 Nov. 2018, https://doi.org/10.3390/pharmaceutics10040217.
- Ucisik, Mehmet H et al. "S-layer fusion protein as a tool functionalizing emulsomes and CurcuEmulsomes for antibody binding and targeting." Colloids and surfaces. B, Biointerfaces vol. 128 (2015): 132-139. https://doi.org/10.1016/j.colsurfb.2015.01.055.
- Distributed under Open Access license CC BY 4.0, without modification.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
